Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma
NCT07746960Phase 1Active, not recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2025
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin, raltitrexed, penpulimab and anlotinib in hepatocellular carcinoma (HCC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Objective Response Rate at 1 year. Started Jan 2025; status: active, not recruiting.
02
Drugs
oxaliplatinraltitrexedpenpulimabanlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07746960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746960.